Johnson & Johnson $JNJ Shares Sold by Metis Global Partners LLC

Metis Global Partners LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 23.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 104,121 shares of the company’s stock after selling 31,512 shares during the period. Johnson & Johnson accounts for approximately 0.5% of Metis Global Partners LLC’s investment portfolio, making the stock its 26th largest holding. Metis Global Partners LLC’s holdings in Johnson & Johnson were worth $21,548,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Paragon Private Wealth Management LLC increased its position in Johnson & Johnson by 5.8% in the fourth quarter. Paragon Private Wealth Management LLC now owns 7,378 shares of the company’s stock worth $1,527,000 after buying an additional 404 shares during the period. Red Cedar Investment Management LLC increased its position in Johnson & Johnson by 211.2% in the fourth quarter. Red Cedar Investment Management LLC now owns 16,462 shares of the company’s stock worth $3,407,000 after buying an additional 11,172 shares during the period. First Dallas Securities Inc. increased its position in Johnson & Johnson by 4.6% in the fourth quarter. First Dallas Securities Inc. now owns 11,497 shares of the company’s stock worth $2,379,000 after buying an additional 501 shares during the period. GW&K Investment Management LLC increased its position in Johnson & Johnson by 2.5% in the fourth quarter. GW&K Investment Management LLC now owns 3,930 shares of the company’s stock worth $813,000 after buying an additional 95 shares during the period. Finally, Outlook Wealth Advisors LLC increased its position in Johnson & Johnson by 2.5% in the fourth quarter. Outlook Wealth Advisors LLC now owns 12,821 shares of the company’s stock worth $2,653,000 after buying an additional 307 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson is drawing bullish attention from commentators and market personalities, with Jim Cramer highlighting its “great new drug profits” and strong balance sheet, which reinforces the company’s defensive appeal and dividend reputation. Jim Cramer Applauds Johnson & Johnson’s “Great New Drug Profits, Triple-A Balance Sheet”
• Positive Sentiment: JNJ continues to strengthen its oncology pipeline after agreeing to buy Firefly Bio for $1 billion, a move aimed at expanding its KRAS-focused cancer treatment platform and supporting long-term growth. Johnson And Johnson Buys Firefly Bio To Deepen Oncology Growth Story
• Positive Sentiment: The company’s CEO said a cure for certain cancers is a realistic goal, which underscores management’s confidence in J&J’s pipeline and may help investor sentiment around future drug innovation. Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal
• Positive Sentiment: Johnson & Johnson was also highlighted in articles calling it a durable “healthcare king” and a stock investors would buy again in a reset portfolio, reinforcing the view that it remains a high-quality defensive name. Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond
• Neutral Sentiment: J&J also received a financing-related mention because its venture arm participated in a FesariusTherapeutics Series A round, a modest signal of ongoing innovation exposure but not a direct earnings driver. FesariusTherapeutics Closes Oversubscribed $20M Series A, Led by Jefferson Life Sciences, and Backed by NY Ventures, and the American Society of Plastic Surgeons
• Negative Sentiment: Offsetting the optimism, a Los Angeles jury awarded $32 million in an asbestos-related talc case, renewing legal risk concerns that have long weighed on J&J shares. Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Analyst Ratings Changes

Several equities research analysts have weighed in on JNJ shares. Citigroup increased their target price on Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Guggenheim raised their price target on Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a report on Monday, April 20th. Morgan Stanley set a $283.00 price target on Johnson & Johnson in a report on Wednesday, April 15th. Barclays raised their price target on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. Finally, Johnson Rice raised Johnson & Johnson from a “hold” rating to an “outperform” rating in a report on Wednesday, May 13th. Twenty equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.04.

Johnson & Johnson Price Performance

Shares of JNJ opened at $238.88 on Thursday. The firm has a market capitalization of $575.04 billion, a price-to-earnings ratio of 27.62, a price-to-earnings-growth ratio of 2.32 and a beta of 0.26. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a one year low of $149.04 and a one year high of $251.71. The stock’s fifty day moving average is $231.70 and its 200-day moving average is $226.87.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.